QSR to QMSR: What to Change in Your Procedures
Updated: Nov 10
Reviewed by Aaron Lyon, President of A.P. Lyon and former Director of Quality Assurance and International Regulatory, with more than 30 years in medical device quality. Last reviewed November 10, 2026.
Since February 2, 2026, FDA has inspected medical device manufacturers under the Quality Management System Regulation (QMSR), the amended 21 CFR Part 820. The QMSR replaced the old Quality System Regulation (QSR) by incorporating ISO 13485:2016 by reference and keeping a short list of FDA-specific requirements on top.
Many manufacturers, especially smaller firms that never pursued ISO 13485 certification, still run procedures written for the QSR. Those procedures cite sections that no longer exist, define records under names the regulation no longer uses, and in some cases tell staff to withhold records that FDA can now ask to see. An investigator who opens a procedure citing 21 CFR 820.181 learns in seconds that the quality system has not been updated.
The fix is rarely a new quality system. For most firms it is a disciplined revision of the documents they already have. This guide explains what changed, what to change in each procedure, and how to work through the update without creating new problems.
What the QMSR actually changed
At the level of the regulation, four things matter for your procedures.
ISO 13485:2016 is now the core requirement. Section 820.10 requires manufacturers to meet the requirements of ISO 13485:2016, as incorporated by reference, for the clauses the regulation applies. Most of the old QSR subparts, from management responsibility to CAPA, are replaced by the corresponding ISO 13485 clauses.
FDA kept some requirements of its own. The QMSR adds or keeps a handful of FDA-specific provisions, chiefly:
definitions in 820.3, which add to or override the ISO 13485 and ISO 9000 definitions for FDA purposes;
requirements in 820.10 that link the quality system to other FDA regulations, such as medical device reporting (Part 803), corrections and removals (Part 806) and unique device identification (Part 830);
record content in 820.35, including what complaint records and servicing records must contain, and UDI in the records for each device or batch;
labeling and packaging controls in 820.45, covering inspection of labeling for accuracy, release, storage and handling to prevent mix-ups.
The QSR vocabulary is gone. The regulation no longer requires a device master record, design history file or device history record by those names. ISO 13485 uses the medical device file (clause 4.2.3), the design and development file (7.3.10) and a record for each device or batch (7.5.1). "Management with executive responsibility" becomes top management.
Some records are no longer shielded from inspection. Under the QSR, FDA did not review management review reports, internal quality audit reports and supplier audit reports during routine inspections. That exception is not in the QMSR. Those records can now be requested and read.
Always check the exact wording in the current text of 21 CFR Part 820 on eCFR and in your licensed copy of ISO 13485:2016. This guide paraphrases both.
Start with a gap assessment, not a rewrite
Before you open a single procedure, map your quality system against the new requirements. A practical gap assessment works section by section through the old QSR, because that is how your procedures are organized today:
for each QSR section, identify the ISO 13485 clause and any FDA provision that now governs it;
note what is genuinely different, not just renumbered;
record what evidence shows you already comply, and what is missing;
give every gap an owner and a due date.
For most firms the assessment produces two very different lists. The long list is references and terminology: every procedure cites 820.xx and uses QSR record names. The short list is substance: a few places where ISO 13485 asks for more than the QSR did. Plan them separately. The long list is clerical work that can be batched. The short list needs real process changes and training.
The substantive gaps that come up most often
These are the areas where firms moving from a QSR-based system most often find real gaps rather than wording problems.
A risk-based approach across the QMS. The QSR mentioned risk analysis mainly in design validation. ISO 13485 expects a risk-based approach to the control of QMS processes (4.1.2) and risk management throughout product realization (7.1). If risk management lives only in your design files, extend it to supplier controls, process validation, software validation and nonconformance decisions.
Supplier controls proportionate to risk. ISO 13485 7.4.1 asks for supplier evaluation, selection, monitoring and re-evaluation criteria that are proportionate to the risk of the supplied product. An approved supplier list built on questionnaires alone may not show that proportionality.
Management review inputs. ISO 13485 5.6.2 lists specific inputs, including feedback, complaint handling, reporting to regulatory authorities, audits, process and product monitoring, CAPA, follow-up actions, changes that could affect the QMS, recommendations for improvement, and new or revised regulatory requirements. Many QSR-era review agendas cover fewer topics.
Software validation for QMS tools. ISO 13485 4.1.6 requires validation of computer software used in the quality management system, proportionate to risk, in addition to production and measurement software. Your complaint database, document control system and training tracker are in scope.
Work environment and contamination control. Clause 6.4 requires documented requirements for the work environment where it can affect product quality, and controls on contamination for sterile and other relevant products.
Medical device file content. A DMR assembled for the QSR usually maps well, but check it against 4.2.3: description and intended use, labeling and instructions for use, product specifications, manufacturing, packaging, storage, handling and distribution specifications, measuring and monitoring procedures, and installation and servicing requirements where applicable.
Complaint and servicing record content. Compare your complaint form with the record content in 820.35 and ISO 13485 8.2.2, including the decision on whether the event is reportable under Part 803, and make sure servicing records are analysed for complaints.
Revising each procedure: a repeatable method
Once the gap assessment is done and the quality manual states how you will handle record names, every procedure can be revised the same way. Working through the same eight checks each time makes the update faster and keeps the system consistent.
Title and header. Replace "Quality System Regulation" and "QSR" with "QMSR" or with "ISO 13485:2016 and 21 CFR Part 820".
Applicable documents. Cite ISO 13485:2016, 21 CFR Part 820, and the other FDA regulations the procedure touches, such as Parts 803, 806, 821 or 830. Add ISO 14971 where risk management applies.
Definitions. Delete QSR-only definitions. Refer instead to ISO 13485:2016, ISO 9000:2015 clause 3 and 21 CFR 820.3.
Section citations. Replace each 820.xx citation with the ISO 13485 clause it now maps to. Keep a 21 CFR 820 citation only where FDA has its own requirement, chiefly 820.10, 820.35 and 820.45.
Record names. Rename or map DMR, DHF and DHR exactly as the quality manual says.
Roles. Replace "management with executive responsibility" with top management, and check that the management representative's duties match ISO 13485 5.5.2.
Substance. Read the ISO 13485 clause the procedure implements and close any gap the assessment found.
Inspection access. Remove any statement that management review, internal audit or supplier audit reports are confidential from FDA.
Before and after: what the edits look like
A few examples show the scale of most changes.
A citation. Before: "Corrective and preventive actions shall be handled per 21 CFR 820.100." After: "Corrective and preventive actions shall be handled per ISO 13485:2016 clauses 8.5.2 and 8.5.3, as required by 21 CFR 820.10."
A record name. Before: "The DHR shall include the dates of manufacture, quantity manufactured and quantity released." After: "The production record for each batch (formerly the device history record) shall include the dates of manufacture, the quantity manufactured, the quantity approved for distribution, and the device identification, including the UDI where required."
A role. Before: "Management with executive responsibility shall review the suitability and effectiveness of the quality system." After: "Top management shall review the quality management system at planned intervals, using the inputs in ISO 13485:2016 clause 5.6.2."
Inspection access. Before: "Management review minutes are confidential and are not shown to FDA investigators." After: "Management review records are quality records and are made available for FDA inspection on request."
None of these is difficult on its own. The work is in doing them consistently across forty or fifty documents, and in noticing the places where the new clause asks for something the old procedure never did.
Rename the records, or keep the old names?
You have two acceptable choices for DMR, DHF and DHR.
Rename. Adopt the ISO 13485 names throughout: medical device file, design and development file, and batch or production record. This is cleanest for firms that also sell outside the US or plan ISO 13485 certification.
Keep and map. Keep the familiar names internally and add a mapping in the quality manual, for example "the device master record (DMR) is our medical device file as required by ISO 13485:2016 clause 4.2.3". This avoids retraining production staff on new names and avoids changing forms that work.
Either approach can satisfy an investigator. What causes trouble is mixing both without explanation, so that one procedure says DHR, another says batch record, and nobody can say whether they are the same thing. Decide once, write the decision in the quality manual, and follow it everywhere.
Do not rewrite historical records. Records made under the QSR stay as they are. Changing old records to use new names, or to suggest that activities were done under requirements that were not yet in effect, creates a record integrity problem far worse than an outdated term.
Prepare for inspections under the QMSR
FDA has said that it will inspect under the QMSR with a revised approach that replaces the old QSIT technique. Whatever the details of the inspection model, three practical consequences follow for manufacturers.
Write management reviews and audit reports as if an investigator will read them. Because they can. Minutes should be factual, complete and show decisions and follow-up. Internal audit reports should state their findings plainly and link to corrective actions.
Expect investigators to follow risk. ISO 13485 places risk in nearly every process. Be ready to show how risk informed your supplier controls, validation decisions and nonconformance dispositions.
Make the regulatory cross-reference easy to find. A short table in the quality manual mapping each QMSR requirement, including the FDA-specific provisions, to the procedure that implements it saves time in the first hour of an inspection and shows the system was updated deliberately.
A realistic sequence
For a small or mid-sized device manufacturer, the update usually runs in this order over two to four months:
Complete the gap assessment with process owners.
Revise the quality manual first: QMSR statement, scope and applicability assessment, definitions, record naming decision and the regulatory cross-reference.
Revise the procedures with substantive gaps, and train the people who use them.
Batch the reference and terminology updates for all other procedures and forms through document control.
Run an internal audit against the QMSR, including the FDA-specific provisions.
Take the results to management review, using the full ISO 13485 5.6.2 input list.
Tools for the update
The QMSR Gap Kit follows this method. It includes a 32-row gap assessment workbook that maps each old QSR section to the ISO 13485 clause and FDA provision that replace it, a terminology and records map for DMR, DHF and DHR, a procedure update guide with before and after wording and a procedure-by-procedure checklist, an inspection readiness checklist, and a QMSR-ready quality manual with organization chart and process interaction diagram. It costs $495 for a single site.
If the gap assessment shows that whole procedures are missing, a complete system written to the QMSR from the start, such as the ISO 13485 QMS Base, is the better starting point, and what you paid for the kit in the last 60 days is credited toward it. For help choosing, see How to Choose a Medical Device Quality Management System.
Related guides: How to Keep Your QMS Documents Current When Standards Change.
Not sure where your quality system stands? Take the free QMS gap check: about 20 questions, an instant report of your gaps by clause, and the procedures that close each one.
Just getting started? The free Startup Quality Plan shows which procedures you need now, which can wait, and how long they take to put in place.
Need only a few procedures? In Build Your QMS you can pick exactly the ISO 13485 and QMSR procedures you need and see the price before checkout.
This guide summarizes and paraphrases 21 CFR Part 820 and ISO 13485:2016. It is not legal advice. Confirm requirements against the current text of the regulation and your licensed copy of the standard.



Comments